How one family cut its annual insulin bill by 88%

Two insulin-dependent people in one household on a single insurance plan with a substantial deductible. Basal and rapid-acting insulin for both, plus consumables — pen needles, test strips and continuous glucose monitoring sensors for the daughter.

The father had started quietly reducing his own basal dose so his daughter's supply would never be interrupted. His HbA1c had drifted upward over eighteen months and neither he nor his physician had connected that trend to cost.

The diabetes team addressed this across two appointments. Every change was clinical, and glucose monitoring was intensified during the transition.

1. 1Enrolled both members in manufacturer insulin cost-cap programmes they were eligible for but had never applied to.
2. 2Switched the father's basal insulin to a biosimilar glargine with the endocrinologist's agreement.
3. 3Moved the father from prefilled pens to vial-and-syringe delivery after a technique assessment.
4. 4Consolidated to 90-day supplies instead of monthly fills.
5. 5Sourced pen needles and test strips as unbranded equivalents rather than the branded originals.

Insulin changes require close observation. The team set a structured two-week protocol before either member changed product.

• Increased glucose checks for two weeks after each change, including overnight readings.
• A written hypoglycaemia action plan for both members and for the school.
• One change at a time, never both members simultaneously.
• Telephone review at seven days and clinic review at four weeks.
• HbA1c repeated at three months for both.

At the three-month review, the father's HbA1c had improved for the first time in two years — not because of a better insulin, but because he was finally taking the full prescribed dose. His daughter's control remained stable throughout.

The clinically important result was the end of rationing. The financial result made that possible.

This is a composite case study. It illustrates a real, documented price pattern using a representative patient profile rather than a specific identifiable individual. Figures are reference ranges, not quotations, and outcomes vary by person, dose and market.

We publish these because abstract percentages do not communicate what a price gap means to a household. A number like '98% cheaper' is forgettable. A monthly bill that drops from an impossible figure to an affordable one is not.

Nothing here is a recommendation to change your own treatment. Every switch described was made with a prescriber's involvement, and yours should be too.

Jivan publishes pricing and educational information only. Do not start, stop, substitute or re-dose any medicine without a licensed physician's approval.